These results uncovered the important role of LINK-A inhibition in overcoming intrinsic Ibrutinib resistance by regulating the AKT/Bcl2-mediated anti-apoptosis pathway, and might provide a therapeutic opportunity for Ibrutinib-resistant MCL patients. This evidence concerns the gene BCL2 and mantle cell lymphoma.